PDF(Pubmed)
Abstract：
We report the first case of relapsing anti-GBM disease secondary to alemtuzumab in a 24-year-old female with relapsing-remitting multiple sclerosis. Initial anti-GBM disease was detected 10 months after alemtuzumab was given and was diagnosed by demonstrating high anti-GBM antibody titers and with a confirmatory kidney biopsy. The patient presented with a rapidly progressive glomerulonephritis with no pulmonary involvement. After appropriate treatment, the patient went into remission with undetectable anti-GBM antibodies. However, 20 months later, the patient re-presented with relapsing anti-GBM disease. Despite aggressive treatment, the patient became dialysis-dependent.
摘要：
我们报告了第一例复发缓解型多发性硬化症的24岁女性中继发于阿仑珠单抗的复发性抗GBM疾病。在给予阿仑珠单抗10个月后检测到初始抗GBM疾病，并通过证明高抗GBM抗体滴度和确认肾活检来诊断。该患者表现为快速进行性肾小球肾炎，无肺部受累。经过适当的治疗，患者因检测不到抗GBM抗体而进入缓解期.然而,20个月后,患者再次表现为复发性抗GBM疾病。尽管积极治疗，患者开始依赖透析.
